Management of advanced ovarian cancer in Spain : an expert Delphi consensus
Redondo Sánchez, Andrés (Universidad Autónoma de Madrid)
Oaknin, Ana (Vall d'Hebron Institut d'Oncologia)
Rubio, Maria Jesus (Universidad de Córdoba)
Barretina-Ginesta, Maria-Pilar (Universitat de Girona)
de Juan, Ana (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria))
Manso, Luis (Hospital Universitario 12 de Octubre (Madrid))
Romero, Ignacio (Instituto Valenciano Oncologia)
Martin-Lorente, Cristina (Institut d'Investigació Biomèdica Sant Pau)
Poveda, Andres (Hospital Quironsalud, Valencia)
Gonzalez-Martin, Antonio (Clínica Universidad de Navarra)
Universitat Autònoma de Barcelona

Data:	2021
Resum:	To determine the state of current practice and to reach a consensus on recommendations for the management of advanced ovarian cancer using a Delphi survey with a group of Spanish gynecologists and medical oncologists specially dedicated to gynecological tumors. The questionnaire was developed by the byline authors. All questions but one were answered using a 9-item Likert-like scale with three types of answers: frequency, relevance and agreement. We performed two rounds between December 2018 and July 2019. A consensus was considered reached when at least 75% of the answers were located within three consecutive points of the Likert scale. In the first round, 32 oncologists and gynecologists were invited to participate, and 31 (96. 9%) completed the online questionnaire. In the second round, 27 (87. 1%) completed the online questionnaire. The results for the questions on first-line management of advanced disease, treatment of patients with recurrent disease for whom platinum might be the best option, and treatment of patients with recurrent disease for whom platinum might not be the best option are presented. This survey shows a snapshot of current recommendations by this selected group of physicians. Although the majority of the agreements and recommendations are aligned with the recently published ESMO-ESGO consensus, there are some discrepancies that can be explained by differences in the interpretation of certain clinical trials, reimbursement or accessibility issues.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Ovarian cancer ; Advanced disease ; Recurrent disease ; Management ; Consensus
Publicat a:	Journal of Ovarian Research, Vol. 14 (may 2021) , ISSN 1757-2215

DOI: 10.1186/s13048-021-00816-x
PMID: 34039386

12 p, 4.7 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats